WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013116781) ALK1 ANTAGONISTS AND THEIR USES IN TREATING RENAL CELL CARCINOMA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/116781    International Application No.:    PCT/US2013/024510
Publication Date: 08.08.2013 International Filing Date: 01.02.2013
IPC:
A61K 38/00 (2006.01), A61K 38/16 (2006.01), A61K 31/40 (2006.01)
Applicants: ACCELERON PHARMA INC. [US/US]; 128 Sidney Street Cambridge, Massachusetts 02139 (US).
BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue Boston, Massachusetts 02215 (US)
Inventors: BHATT, Rupal S.; (US).
KUMAR, Ravindra; (US).
MIER, James W.; (US).
PEARSALL, Robert; (US).
SHERMAN, Matthew; (US).
SOLBAN, Nicolas; (US)
Agent: HOOVER, Kenley K.; Sterne, Kessler, Goldstein & Fox P.L.L.C. 1100 New York Avenue N.W. Washington, District of Columbia 20005 (US)
Priority Data:
61/593,864 02.02.2012 US
61/597,124 09.02.2012 US
Title (EN) ALK1 ANTAGONISTS AND THEIR USES IN TREATING RENAL CELL CARCINOMA
(FR) ANTAGONISTES D'ALK1 ET LEURS UTILISATIONS DANS LE TRAITEMENT DU NÉPHROCARCINOME
Abstract: front page image
(EN)In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
(FR)Dans certains aspects, la présente invention concerne l'utilisation d'un polypeptide comprenant une partie de liaison au ligand du domaine extracellulaire du polypeptide kinase analogue à l'activine 1 (ALK1) pour inhiber la croissance tumorale d'un néphrocarcinome (RCC) in vivo. Dans d'autres aspects, l'invention concerne le fait qu'un polypeptide comprenant une partie de liaison au ligand du domaine extracellulaire d'ALK1 augmente de façon spectaculaire la capacité d'un inhibiteur de tyrosine kinase de récepteur standard à inhiber la croissance tumorale d'un RCC in vivo.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)